8-K filing — Atkore Inc. (ATKR)
Filed: 2026-10-08 AccNo: 0001666138-26-000039 Size: 173 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Snap To Rally More Than 217%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed outlook on top names. Complete view of analyst rating changes, including upgrades/downgrades, on analyst ratings page.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Halper Sadeh LLC is Investigating Whether BZH, CBAN, ATKR, BGMS are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers. The investigations cover Beazer Homes' $33.50/share sale, Colony Bankcorp's merger, Atkore's $95.00/share sale, and Bio Green Med Solution's merger.
Channel Base Market Poised for Growth Through 2031 as Infrastructure Upgrades and Industrial Modularization Accelerate Demand
The global channel base market, valued at USD 130-220 million, is projected to grow at a CAGR of 2.5-4.3% through 2031, driven by demand for pre-assembled, BIM-ready systems that reduce labor costs by 20-30%. North America leads with 35-39% market share, while Asia-Pacific is the fastest-growing region. Key trends include standardization, modular construction, and regionalization of supply chains, with manufacturers differentiating through digital integration, corrosion resistance, and engineering support.
8-K filing — Cigna Group (CI)
Filed: 2026-10-09 AccNo: 0001140361-26-039271 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Humana Reaffirms FY26 Adjusted EPS Guidance Of At Least $9; Exceeding Goal Of Top Quartile Results In 2027 Medicare Advantage Star Ratings; Expects 2028 Benefit For One-Time Investments And Return To Shareholders
Humana affirms its guidance of at least $9.00 in adjusted earnings per common share ("Adjusted EPS"), for the year ending December 31, 2026 ("FY 2026"). This guidance is consistent with the guidance
CMS Releases 2027 Medicare Advantage And Part D Star Ratings, With 37% Of MA-PD Contracts Earning Four Or More Stars And 71% Of Enrollees In High-Rated Plans